Research Article
Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis
Table 4
The baseline characteristics according to the ICPI group in the ICIs cohort.
| | Low-risk ICPI | Moderately high-risk ICPI | value | | n = 101 | n = 42 |
| | Sex | | | 0.314 | | Male | 19 (18.8) | 5 (11.9) | |
| | Age (year) | | | 0.923 | | ≥65 | 40 (39.6) | 17 (40.5) | |
| | Smoking status | | | 0.031 | | Nonsmoker | 21 (20.8) | 16 (38.1) | | | Smoker | 80 (79.2) | 26 (61.9) | |
| | Histology | | | 0.960 | | Adenocarcinoma | 52 (51.5) | 21 (50.0) | | | Squamous | 43 (42.6) | 18 (42.9) | | | NSCLC-others | 6 (5.9) | 3 (7.1) | |
| | KRAS alteration status | | | 0.496 | | KRAS wild-type | 43 (42.6) | 22 (52.4) | | | KRAS-mutant | 5 (5.0) | 1 (2.4) | | | NA | 53 (52.5) | 19 (45.2) | |
| | PD-L1 status | | | 0.622 | | Negative | 6 (5.9) | 2 (4.8) | | | Positive | 15 (14.9) | 9 (21.4) | | | NA | 80 (79.2) | 31 (73.8) | |
| | PS (ECOG) | | | 0.085 | | 0-1 | 101 (100) | 40 (95.2) | | | ≥2 | 0 (0) | 2 (4.8) | |
| | Stage | | | 0.090 | | I-II | 7 (6.9) | 0 (0) | | | IIIA | 8 (7.9) | 1 (2.4) | | | IIIB–IV | 86 (85.1) | 41 (97.8) | |
| | Metastatic sites number | | | <0.001 | | <2 | 50 (49.5) | 7 (16.7) | | | ≥2 | 51 (50.5) | 35 (83.3) | |
| | Metastatic sites | | | | | Live | 9 (8.9) | 9 (21.4) | 0.04 | | Bone | 16 (15.8) | 18 (42.9) | 0.001 | | Brain | 14 (13.9) | 5 (11.9) | 0.754 | | WBC (×109/L) | 6.44 (5.22–7.75) | 8.11 (6.09–10.13) | <0.001 | | ANC (×109/L) | 4.04 (2.81–5.10) | 6.02 (4.69–8.00) | <0.001 | | ALC (×109/L) | 1.60 (1.13–1.95) | 1.01 (0.81–1.54) | <0.001 | | MON (×109/L) | 0.54 (0.39–.071) | 0.61 (0.41–0.75) | 0.879 | | RDW (%) | 13.4 (13.0–14.6) | 14.6 (13.6–14.9) | 0.150 | | PLT (×109/L) | 231 (163–289) | 212 (180–309) | 0.929 | | ALB (g/L) | 42.93 ± 3.61 | 36.49 ± 4.26 | <0.001 | | PLR | 139.0 (110.1–198.4) | 218.5 (144.2–284.5) | <0.001 | | dNLR | 1.93 (1.16–2.28) | 3.62 (2.51–4.31) | <0.001 |
| | ICIs drug | | | 0.028 | | Sintilimab | 18 (90) | 2 (10) | | | Nivolumab | 21 (56.8) | 16 (43.2) | | | Pembrolizumab | 62 (72.1) | 24 (27.9) | |
| | ICIs treatment modality | | | 0.011 | | ICI monotherapy | 26 (56.5) | 20 (43.5) | | | ICI + chemotherapy | 75 (77.3) | 22 (22.7) | | | ICI + antiangiogenic | | | |
| | ICIs line | | | 0.168 | | 1 | 36 (35.6) | 10 (23.8) | | | ≥2 | 65 (64.4) | 32 (76.2) | |
| | Previous treatments | | | | | Chemotherapy | 61 (60.4) | 28 (66.7) | 0.481 | | Radiotherapy | 11 (10.9) | 12 (28.6) | 0.009 | | EGFR-TKI | 8 (7.9) | 4 (9.5) | 0.753 | | Antiangiogenic | 16 (15.8) | 9 (21.4) | 0.423 | | Surgery | 9 (8.9) | 4 (9.5) | 0.156 |
| | Disease response | | | 0.103 | | CR | 2 (2.0) | 0 (0) | | | PR | 44 (43.6) | 16 (38.1) | | | SD | 42 (41.6) | 13 (31.0) | | | PD | 13 (12.9) | 13 (21.0) | |
| | Response rates | | | | | ORR (%) | 45.5 | 38.1 | 0.714 | | DCR (%) | 87.1 | 69 | 0.031 |
|
|
